Proactiveinvestors recommends
Additional Information
Market: LON
Sector: Pharmaceuticals
EPIC: AMP
Amphion Innovations
www.amphionplc.com

Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

Full Amphion Innovations profile here
Pdf

Amphion Innovations moves into the black during first half

29th Sep 2011, 10:33 am by Jon Mainwaring

 

Interim results from Amphion Innovations (LON:AMP) show that the technology commercialisation firm moved into the black during the first six months of the year on increased revenues.

The firm’s revenues for the half-year period to June 30 were US$2.6 million, compared with US$1.6 million in H1 2010, while its operating loss was reduced to US$130,244 from US$1.1 million. But gains on investments as well as interest income meant that the firm actually posted a profit on the pre-tax line of £270,403 (H1 2010: £2.7 million).

Amphion’s DataTern intellectual property-licensing subsidiary, with the help of law firm McCarter & English, continues to make progress with its patent-enforcement activities against a number of companies regarding its next-generation business software: ObjectSpark.  DataTern has taken “concrete steps” to combat allegations by Microsoft and SAP and to bolster its own patent rights. The first of these was a filing of a motion in New York to dismiss, or at least stay these actions, while DataTern continues litigations in Texas against users of the patented technology.

Meanwhile, DataTern has filed an application with the US Patent and Trademark Office to re-examine the business’s ‘402 patent. Under this procedure a patent may be maintained as it is, expanded, reduced or even rendered invalid, but Amphion said that DataTern’s confidence in the validity of the patent justifies exposing it to re-examination.

DataTern saw a substantial increase in income from its licensing activities during the first half, with its revenues increasing to US$2 million (H1 2010: $732,050).

Among Amphion’s ‘Partner Companies’ Kromek, its digital X-ray business, continues to make progress and recently received additional orders for its GR1 instrument, which is being used in Japan for the decommissioning of the Fukushima nuclear power plant. Meanwhile, Motif BioSciences is progressing towards the consummation of an “important and exciting” partnership with one of the leading Indian pharmaceutical services companies and other Partner Companies are also doing well, the firm said.

“We are pleased to be reporting an improved set of results for the company,” said Richard Morgan, Amphion’s chairman and chief executive officer. “Alongside the progress being made by each of the Partner Companies, we believe DataTern is starting to benefit from the support of our new IP litigation partner and as a result the potential of this business has increased substantially.  Improved performance by DataTern should in due course lead to an improvement in Amphion's results, with a positive impact on Amphion's financial condition and its ability to fund and grow its Partner Companies.”

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.